| Followers | 100 |
| Posts | 6718 |
| Boards Moderated | 0 |
| Alias Born | 05/21/2009 |
Sunday, November 15, 2009 10:21:43 PM
IMO you will probably not get 18. They may be gone forever. The market quite liked the 10Q and the PR especially the PR which foresees the trial numbers being made up to desired levels early Q1 2010. Let's face it growing exposure of MSBT plus flu and swine on the rise it's probably a done deal.
As for the science itself, confidence simply continues to grow among investors. The CE Mark, anticipated rapid commercialisation throughout Europe and FDA approval are seen as in the bag IMO. I expect a steady rise to 40 cent by EOY then a pullback as we wait on news. If the news is good, we could be saying hello to $2 real fast.
IMO you should pick up some 19s tomorrow but buying at the ask can't hurt with the outlook I think is ahead.
The above is JMO and none of it should be regarded as a buy, sell or hold signal. Do your own DD. I just happen to love this stock and my shares are held extremely tight.
As for the science itself, confidence simply continues to grow among investors. The CE Mark, anticipated rapid commercialisation throughout Europe and FDA approval are seen as in the bag IMO. I expect a steady rise to 40 cent by EOY then a pullback as we wait on news. If the news is good, we could be saying hello to $2 real fast.
IMO you should pick up some 19s tomorrow but buying at the ask can't hurt with the outlook I think is ahead.
The above is JMO and none of it should be regarded as a buy, sell or hold signal. Do your own DD. I just happen to love this stock and my shares are held extremely tight.
Freakin' Sweet!!
Recent CTSO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 08:21:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:05:35 PM
- CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update • PR Newswire (US) • 05/13/2026 08:00:00 PM
- CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights • PR Newswire (US) • 04/30/2026 11:00:00 AM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/15/2026 09:18:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 11:00:20 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 11:04:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:27:51 PM
- CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 03/25/2026 08:05:00 PM
- CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 • PR Newswire (US) • 03/19/2026 01:44:00 PM
- CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 03/05/2026 12:00:00 PM
- CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update • PR Newswire (US) • 01/12/2026 12:00:00 PM
- CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025 • PR Newswire (US) • 12/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 02:09:45 AM
- Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London • PR Newswire (US) • 11/17/2025 10:42:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:34:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 09:32:19 PM
- CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update • PR Newswire (US) • 11/13/2025 09:05:00 PM
- CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London • PR Newswire (US) • 11/11/2025 12:00:00 PM
- CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 10/30/2025 11:00:00 AM
- In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer • PR Newswire (US) • 10/28/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2025 08:20:54 PM
- CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen • PR Newswire (US) • 09/29/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2025 08:35:38 PM
- CytoSorbents Provides DrugSorb-ATR Regulatory Update • PR Newswire (US) • 09/16/2025 11:00:00 AM
